178 related articles for article (PubMed ID: 38411882)
1. Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer.
Li Y; Qin J; Chen G; Wu W; Sun X
Int J Clin Oncol; 2024 Apr; 29(4):427-441. PubMed ID: 38411882
[TBL] [Abstract][Full Text] [Related]
2. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
4. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
[TBL] [Abstract][Full Text] [Related]
5. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
7. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
[TBL] [Abstract][Full Text] [Related]
9. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
10. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
11. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
12. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K
Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505
[TBL] [Abstract][Full Text] [Related]
13. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
14. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
[TBL] [Abstract][Full Text] [Related]
15. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
16. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.
Dhakal HP; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Bassarova A; Holm R; Giercksky KE; Nesland JM
Histopathology; 2012 Sep; 61(3):350-64. PubMed ID: 22690749
[TBL] [Abstract][Full Text] [Related]
18. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
19. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
